Neumora Therapeutics, Inc. (NMRA NASDAQ) stock market data APIs
$1.2638
0.07(5.5%)
as of July 14, 2025
Try our APIs with
free plan!
Neumora Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Prev. Close
1.2638
Open
1.3352
High
1.3474
Low
1.132
52 wk Range
0.611-17.1874
Market Cap
209 M
Shares Outstanding
162 M
EPS
-0.42
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neumora Therapeutics, Inc. data using free add-ons & libraries
Get Neumora Therapeutics, Inc. Fundamental Data
Neumora Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -273 696 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neumora Therapeutics, Inc. News
New
H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock
Investing.com - H.C. Wainwright has reiterated its Buy rating and $18.00 price target on Neumora Therapeutics (NASDAQ:NMRA) following the company’s selection of a new lead M4 PAM candidate for sch...
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbi...
Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks
The market has stayed flat over the past week, but it is up 13% over the past year, with earnings forecasted to grow by 15% annually. In such a setting, investors often look for stocks that combine va...
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) br...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
